| Not Yet Recruiting | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma NCT07459608 | Henan Cancer Hospital | Phase 2 |
| Not Yet Recruiting | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478 | Newave Pharmaceutical Inc | Phase 3 |
| Recruiting | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998 | Zulfa Omer | Phase 2 |
| Recruiting | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of NCT06978088 | Zulfa Omer | Phase 2 |
| Recruiting | A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lympho NCT06708897 | Lomond Therapeutics Holdings, Inc. | Phase 1 |
| Not Yet Recruiting | A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy NCT06476899 | Fei Li | Phase 2 |
| Recruiting | Current Status of BTKi Treatment for CLL/SLL in China NCT06508684 | The First Affiliated Hospital with Nanjing Medical University | — |
| Recruiting | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refrac NCT05791409 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 1 / Phase 2 |
| Recruiting | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagn NCT06319456 | Ascentage Pharma Group Inc. | Phase 3 |
| Recruiting | Global Trial in APG2575 for Patients With CLL/SLL NCT06104566 | Ascentage Pharma Group Inc. | Phase 3 |
| Unknown | the Real World Study of Orelabrutinib in the Treatment of CLL/SLL NCT05975164 | Shandong University | — |
| Not Yet Recruiting | Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL NCT05918276 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Unknown | Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymp NCT05920668 | Wang Xin | — |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Active Not Recruiting | French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real NCT05590702 | French Innovative Leukemia Organisation | — |
| Unknown | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies NCT05487651 | Athenex, Inc. | Phase 1 |
| Withdrawn | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL NCT05365100 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Withdrawn | Early Intervention With Acalabrutinib in Patients With High Risk CLL NCT04660045 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignan NCT05269940 | Nanjing Zenshine Pharmaceuticals | Phase 1 / Phase 2 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Unknown | A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib NCT05491044 | Peking University People's Hospital | Phase 2 |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Terminated | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy NCT04149821 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) NCT04523428 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lym NCT04694560 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL NCT04215809 | Ascentage Pharma Group Inc. | Phase 1 |
| Unknown | A Study to Evaluate ICP-022 in Patients With CLL/ SLL NCT03493217 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade NCT00714259 | University of Alabama at Birmingham | Phase 2 / Phase 3 |